HealthQuill SystImmune's
2023: Bristol Myers Squib will pay a total of $8.4 billion to SystImmune Inc., the US arm of Chinese drugmaker Sichuan Biokin Pharmaceutical Co., to jointly develop and market a cancer drug outside China.
Drugs Health Pharma

Bristol Myer to pay China’s drugmaker Sichuan $8.4b to develop cancer drug

HQ Team December 12, 2023: Bristol Myers Squib will pay a total of $8.4 billion to SystImmune Inc., the US arm of Chinese.

Read More
X